Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same authorSame journal

Hoarseness as a Manifestation of Chronic Lymphocytic Leukaemia Involving the Larynx.

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP·2026

Same author

Primary Leiomyosarcoma of the Pancreas with Liver Metastasis: Challenges and Possible Treatment Approaches.

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP·2026

Same author

Paraneoplastic Focal Segmental Glomerulosclerosis in Association With Colon Cancer: A Rare Clinical Case Report.

Clinical case reports·2025

Same author

Gastric carcinoma leading to metastatic spinal cord compression.

JPMA. The Journal of the Pakistan Medical Association·2025

Same author

SEROLOGICAL OUTCOMES OF TREATMENT WITH 3D-CRT AND IMRT IN LOCALIZED PROSTATE CANCER.

Journal of Ayub Medical College, Abbottabad : JAMC·2024

Same author

Well-Differentiated Neuroendocrine of Left Kidney.

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP·2024

Search research articles

Related Experiment Video

Updated: May 18, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Temozolomide for relapsed primary CNS lymphoma.

Asif Husain Osmani¹, Nehal Masood

¹Section of Haematology/Oncology, Department of Medicine, The Aga Khan University Hospital, Karachi. asif.osmani@aku.edu

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP

|September 18, 2012

Summary

Primary CNS lymphoma (PCNSL) is an aggressive brain tumor. A case study shows temozolomide can effectively treat relapsed PCNSL in immunocompetent patients after other therapies failed.

Area of Science:

Neuro-oncology
Hematology
Oncology

Background:

Primary CNS lymphoma (PCNSL) is a rare, aggressive non-Hodgkin's lymphoma affecting the brain.

More Related Videos

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Related Experiment Videos

Last Updated: May 18, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Risk factors for PCNSL in immunocompetent individuals are not well-defined.

PCNSL is more prevalent in older males and strongly associated with Epstein-Barr virus (EBV) in AIDS patients.